The rs2229611 (G6PC:c.*23 T > C) is associated with glycogen storage disease type Ia in Brazilian patients

Franciele Cabral Pinheiroa,b,c,1, Fernanda Sperb-Ludwiga,b,⁎, Juliana Maria Fagundes Verchb,d, Bruna Bento dos Santosa, Carolina Fischinger Moura de Souzae, Ida Vanessa Doederlein Schwartza,b,e

a Post Graduate Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil
b Laboratory of Basic Research and Advanced Investigations in Neurosciences (BRAIN), Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
c Universidade Federal do Pampa (UNIPAMPA), Itaqui, RS, Brazil
d Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil
e Medical Genetics Service, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

ARTICLE INFO

Keywords:
Glycogenosis
GSD Ia
Linkage-disequilibrium
Inborn error of metabolism
Genetic biomarker

ABSTRACT

The rs2229611 SNP (G6PC:c.*23 T > C) in the 3'UTR region of the G6PC gene affects the stability of the glucose-6-phosphatase mRNA and occurs in a higher frequency in patients with glycogenosis Ia (GSD Ia) in some populations. Herein, a group of Brazilian patients (n = 116) was analyzed by NGS and the frequency of rs2229611:T>C was determined. The linkage disequilibrium (LD) between pathogenic variants and the rs2229611:T>C SNP was evaluated. The results showed that the rs2229611:T>C is associated to GSD Ia and is in LD with the most frequent pathogenic variants in Brazilian patients with GSD Ia.

1. Introduction

Glycogenoses (GSDs) consist of a group of inborn errors of metabolism that affect the synthesis or degradation of glycogen. The most frequent and severe is GSD type I, an autosomal recessive disease that affects the glucose-6-phosphatase (G6Pase) complex. Pathogenic variants in G6PC and SLC37A4 genes result in GSD Ia (OMIM 232200) and Ib (OMIM 232200), respectively [1].

To date, 128 pathogenic variants in G6PC have been described in Human Gene Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/ac/index.php?gene=G6PC) [2]. The genotype-phenotype relationship has been narrowed down to a small number of pathogenic variants; for instance, homozygosis for the NM_000151.4:c.648G > T (NP_00142.1:p.?), a splice site variant, is associated with an increased risk of hepatocellular carcinoma [3]. Studies have indicated that GSD Ia phenotypes are influenced by genetic and environmental modifying factors [4]. In this regard, the rs2229611 SNP (NG_011808.1:g.15652 T > C), located at the 3' UTR of G6PC gene, has been shown to be a potential modulating factor for the severity of this disease. Karthi et al. (2017), demonstrated that the G6PC:c.*23C allele results in a shorter half-life mRNA than those resulting from the G6PC:c.*23T allele, also altering the spectrum of regulatory proteins that bind to the G6PC 3' UTR region [5]. In addition, the rs2229611:T > C SNP frequency appears to be higher in patients with GSD Ia than in healthy controls [5–9]. The control sample studied by Lam et al. (1998) (n = 194) [6] was compared to 34 patients with GSD Ia by Wong et al. [7], showing that this SNP is in linkage disequilibrium (LD) with G6PC pathogenic variants, e.g., NM_000151.4:c.247C>T (p.Arg83Cys), NM_000151.4:c.248G>A (p.(Arg83His)) and c.648G > T (p.?) [7].

In order to evaluate the possible effect of the rs2229611 SNP in Brazilian patients with GSD Ia, we studied a cohort of 116 patients with hepatic GSD whose genotype had been previously described by Sperb-Ludwig (2019) [10]. So, we determined whether the frequency of the rs2229611:T > C SNP differs among GSD types and whether this SNP is associated with an earlier onset of symptoms in GSD Ia.

2. Material and methods

The patient genotype for the rs2229611:T > C SNP was determined by bioinformatics analysis of next-generation sequencing (NGS) results using Enlis Genomic (https://www.enlis.com/index.html) and Ion
Table 1
Frequency of the rs2229611 SNP (NM_000151.4:c.*23 T > C) in Brazilian patients with hepatic glycogen storage disease.

| GSD type | Patients (n) | Alleles (n) | G6PCc.*23 T n (%) | G6PCc.*23C n (%) | G6PCc.*23 TT n (%) | G6PCc.*23 TC n (%) | G6PCc.*23CC n (%) |
|----------|--------------|-------------|-------------------|------------------|-------------------|-------------------|------------------|
| Ia       | 50           | 99          | 7 (7.1)           | 92 (92.9)*       | 1(2.0)            | 5 (10.0)          | 44 (88.0)        |
| Others   | 66           | 132         | 44 (33.3)         | 88 (66.7)        | 7 (10.6)          | 30 (45.5)         | 29 (43.9)        |
| Ib       | 23           | 46          | 10 (21.7)         | 36 (78.3)        | ND                | 10 (43.5)         | 13 (56.5)        |
| II       | 13           | 26          | 9 (34.6)          | 17 (65.4)        | 1 (7.7)           | 7 (53.8)          | 5 (38.5)         |
| VI       | 2            | 4           | 1 (25.0)          | 3 (75.0)         | ND                | 1 (50.0)          | 1 (50.0)         |
| IXa      | 16           | 32          | 13 (40.6)         | 19 (59.4)        | 4 (25.0)          | 5 (31.3)          | 7 (43.7)         |
| IXb      | 6            | 12          | 6 (50.0)          | 6 (50.0)         | 1 (16.7)          | 4 (66.7)          | 1 (16.7)         |
| IXc      | 6            | 12          | 5 (41.7)          | 7 (58.3)         | 1 (16.7)          | 3 (50.0)          | 2 (33.3)         |
| Total    | 116          | 231         | 51 (22.1)         | 180 (77.9)       | 8 (6.9)           | 35 (30.2)         | 73 (62.9)        |

Note: The data are presented as number of alleles and the frequency in parenthesis. GSD = glycogen storage disease; ND = not detected; *One patient had consanguineous parents, so one allele was discounted from the analyses. †Indicates the association of rs2229611 with GSD Ia (adjusted residual 4.8; p < 0.05).

Table 2
Parameters of linkage disequilibrium analysis of rs2229611 (NM_000151.4:c.*23 T > C) with common variants in Brazilian patients with glycogen storage disease Ia.

| Variant | D' | r² | LOD |
|---------|----|----|-----|
| c.161A > C (p.Gln54Pro)* | 0.51 | 1 | 0.009 < 2 |
| c.247C > T (p.Arg83Cys)* | 0.85 | 0.043 | ≥2 |
| c.563C > G (splice site)* | 1 | 0.025 | ≥2 |
| c.1093C > T (p.Gln347Ter)* | 0.019 | 0.019 | < 2 |

Note: The LD analysis was performed in Haplovie. 4.2 software. * likely pathogenic
b pathogenic
c LOD values higher than two indicate that LD is significant, this score is influenced by sample size.

4. Discussion
This is the first study that evaluated the frequency of the rs2229611:T > C SNP in patients with different hepatic GSDs. The data showed that the rs2229611:T > C SNP frequency among hepatic GSDs, except GSD Ia, is similar to that observed in controls of the gnomAD database (73.19%). The frequency of this SNP in our group of Brazilian patients with GSD Ia is ~93%, the highest value observed in the patient populations studied so far [5–9]. Our data also showed that the frequency of the G6PCc.*23C allele is different between patients with GSD Ia and with other types of GSD (66.7%).

The gnomAD database analysis reinforced the conclusion of previous studies that the frequency of rs2229611:T > C SNP varies (45–85%) among different populations [5–9]. In this sense, Lam et al. (1998) suggested that rs2229611:T > C SNP could be used as a marker in Chinese and Hispanic populations for both carrier screening and prenatal diagnosis of GSD Ia in families whose two pathogenic variants have not been identified [6]. Thus, based on the rs2229611:T > C SNP frequency in Asian populations in gnomAD (45.6%), the suggested approach may be a good alternative, but in populations such as Finns (81.6%), this method can generate many false positives. In our sample, the frequency of homozygotes G6PCc.*23C is higher in GSD Ia (88%) when compared to other types of GSD (43.9%). Thus, in the Brazilian population, homozygosity of G6PCc.*23C may indicate the diagnosis of GSD Ia in symptomatic patients. Therefore, the high frequency of G6PCc.*23C allele in control populations makes the rs2229611:T > C a
sensitive but non-specific biomarker for the diagnosis of GSD Ia. The higher frequency of the rs2229611:T > C SNP in patients with GSD Ia could be related to the LD between this SNP and pathogenic G6PC variants. The analyses showed that two variants are in LD with the rs2229611:T > C SNP in our group of patients (Table 2). The c.247C > T variant was present in two different haplotypes in Brazil (Table 2), one linked with the G6PC:c.*23T allele. The second haplotype was in LD with the G6PC:c.*23C allele, as showed in Caucasian, Hispanic and Chinese patients [7] and in another group of Brazilian patients [9]. Our data suggest two origins for this allele in the Brazilian population. The c.809G > T (p.Gly270Val) variant could be in LD with the rs2229611:T>C SNP (data not shown) were present in only one or two patients, thus hindering a more robust analysis. However, the only patient who was G6PC:c.*23 TT is also homozygous for the c.809G > T variant, reinforcing this hypothesis. Thirteen pathogenic variants that appear to be in LD with the rs2229611:T > C SNP (data not shown) were present in one or two patients, thus hindering a more robust analysis. Thus, our data reinforce that this SNP is in LD with the most prevalent pathogenic variants in G6PC in the Brazilian patients. The evidence obtained by Karthi and collaborators [5] suggests that the rs2229611:T > C SNP could be associated with greater GSD Ia severity; therefore, the age at symptom onset was analyzed. However, it was not possible to establish an association between this SNP and earlier GSD Ia onset in Brazilian patients. Due to the low frequency of the G6PC:c.*23T allele in the Brazilian patients (7%, Table 1), there was insufficient statistical power to perform an association study. The p.Arg83Cys have been previously evaluated by functional assays, and alone abolishes G6Pase activity [16]. So, the rs2229611:T > C SNP is not expected to increase the severity of GSD Ia when this variant is present. In the analysis of the SNP in constructs containing a 3′UTR portion of the G6PC gene associated with a luciferase expression vector, it was possible to observe the functional involvement of 3′UTR polymorphism rs2229611:T > C in the negative regulation of G6PC expression at mRNA levels, possibly by decreasing its stability [5]. Therefore, when this SNP is associated with pathogenic variants that have some residual activity, this may reflect in greater severity, as the mRNA instability can contribute to abolish the G6Pase activity. Our data suggest the need to study a larger group of patients with GSD Ia who carry the G6PC:c.*23T allele to examine the association of the rs2229611:T > C SNP with the symptom severity, even though this is one of the largest cohorts ever analyzed for this purpose. Another approach would be in vitro expression studies with constructs carrying rs2229611-related variants to determine whether this SNP leads to altered expression levels. This approach would be valid for analyzing variants not yet studied or which are associated with a residual activity of G6Pase.

5. Conclusion

The data confirm that the rs2229611:T > C SNP is also associated to Brazilian patients with GSD Ia and showed the LD of this SNP with the c.247C > T and c.563-3C > G variants, the most frequent ones in this population.

Declaration of Competing Interest

None.

Acknowledgments

The authors acknowledge the FIPE-HCPA, CAPES, CNPq, Brazil and...